NRC FORM 374	NRC	FOF	MS	374
--------------	-----	-----	----	-----

## U.S. NUCLEAR REGULATORY COMMISSION

PAGE \_\_1\_ OF \_3\_ PAGES Amendment No. 49

Corrected copy

## MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

1.	SSI	Licensee M St. Clare Health Center			In accordance v June 21, 2010 3. License number entirety to read	<b>and</b> <i>i</i>	<b>Au</b> 118	<b>gust 11, 2010</b> , 358-01 is amended in its
2.	101	5 Bowles Avenue			4. Expiration date			
	Fen	iton, MO 63026			5. Docket No. 030 Reference No.	)-023	68	
6.		product, source, and/or special nuclear terial	7. Ch	emical a	nd/or physical form		pos	ximum amount that licensee may ssess at any one time under this ense
	Α.	Any byproduct material permitted by 10 CFR 35.100	A.	Any			Α.	As needed
	B.	Any byproduct material permitted by 10 CFR 35.200	B.	Any			В.	As needed
	C.	Any byproduct material permitted by 10 CFR 35.300	C.	Any			C.	As needed (not to exceed 150 millicuries of iodine-131)
	D.	Any byproduct material permitted by 10 CFR 35.400		Medica 2301 to 2335; N Scientii 363; T Corp. 2 Biopha I-125 S Int'l. Br. SA 103 Syncor Medi-P (Echose (Oncos IAI-125 and Imp Corp. 3 Bard B Inc. ST	sources (Best al Int'l. 81-01, 2316, 2331, North American fic Med 3633, heragenics 200, Mills rm. 103 SL and L (Prostaseed); achytherapy 11L and 1251L, BT-125-1, hysics 6733 eed) and 6711 eed), IsoAid A (Advantage), clant Sciences 500 (I-plant); rachtherapy M 1251; LLC IAPd-		D.	4 curies

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE	2	of	3	PAGES
	MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 24-11858-01 Docket or Reference Numbe 030-02368	r				
		Amendment No. 49 Corrected copy					

## 9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
- D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

## CONDITIONS

- 10. Licensed material listed in above. may be used and stored at 1015 Bowles Avenue, Fenton, Missouri.
- 11. The Radiation Safety Officer for this license is Andre Strzembosz, M.D.
- 12. Licensed material is only authorized for use by, or under the supervision of:
  - A. Individuals permitted to work as an authorized user, authorized nuclear pharmacist, and/or authorized medical physicist in accordance with 10 CFR 35.13 and 35.14.
  - B. The following individuals are authorized users for medical use as indicated:

Vincent Q. Joe, M.D.	10 CFR 35.400.
Megan Maine Gau, M.D.	10 CFR 35.100 and 35.200.
Michael G. Beat, M.D.	10 CFR 35.300 and 35.400.
Robert J. Gresick, M.D.	10 CFR 35.100 and 35.200.
Thomas P. Bocchini, M.D.	10 CFR 35.100 and 35.200.
Karen J. Baranski, M.D.	10 CFR 35.100 and 35.200.
James G. Stewart, M.D.	10 CFR 35.100 and 35.200.
Andre Strzembosz, M.D.	10 CFR 35.100, 35.200 and 35.300.
Ronald Palmer, M.D.	10 CFR 35.100, 35.200 and 35.300.
Edwin C. Ernst, III, M.D.	10 CFR 35.100, 35.200 and 35.300.
Larry Paskar, M.D.	10 CFR 35.100 and 35.200.
Authorized Users	Material and Use

13. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE	3	of	3	PAGES
		License Number 24-11858-01					
	MATERIALS LICENSE SUPPLEMENTARY SHEET	Docket or Reference Number 030-02368	er				
		Amendment No. 49	-				De la companya del la companya de la
		Corrected copy					

- 14. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.
- 15. Sealed sources containing licensed material shall not be opened or sources removed from source holders by the licensee.
- 16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
  - A. Letters dated December 17, 2004 (with attached application), December 2, 2005, March 7, 2007, January 22, 2009, June 12, 2009, September 3, 2009; and
  - B. Facsimile dated August 28, 2009.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date SEP 1 6 2010

Toye L. Simmons

Materials Licensing Branch

Region III